Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I) : Initial Choice of Antidepressant Treatment

IntroductionWorking memory dysfunctions are observed in patients with recurrent depressive disorders. These deficits exert negative effects not only on psychological test performance levels but also on the capacity of affected patients to cope with everyday life situations, as well as on decreased remission levels.AimThe goal of the study was to identify possible associations between spatio-visual working memory, evaluated on admission, with the remission degree, assessed after 8-week pharmacotherapy with SSRI in a group of patients with diagnosed depression.Methods141 subjects were examined (patients with depressive disorders, DD: n = 86, healthy subjects, CG: n = 55). Trail Making Test by Reitan (TMT) was used.ResultsCG obtained higher results vs. DD-I patients (the evaluation started on the therapy onset) in TMT A/time (p = 0.09), TMT B/time (p = 0.009). CG demonstrated better results than DD-II patients (following eight weeks of pharmacological treatment) in TMT A (p = 0.11), TMT B (p = 0.85). Compared to DD-I group, DD-II group achieved better results in TMT A (p < 0.001) and TMT B (p < 0.001). The lowest performance levels in TMT A and TMT B may have been related to the highest depression levels after pharmacological treatment.Conclusions1.Depressive disorders are associated with deteriorated efficiency of visual working memory.2.Antidepressant treatment resulted in improved of visual working memory.3.The better performance in TMT on the first day of treatment may have influenced the noted reduction in severity of depressive symptoms after treatment with SSRI.

Download Full-text

Standard Evidence-Based Pharmacological Treatment for OCD

10.1093/med/9780190228163.003.0040 ◽

2017 ◽

Author(s):

Jemma E Reid ◽

Samar Reghunandanan ◽

Ann Roberts ◽

Naomi A Fineberg

Keyword(s):

Quality Of Life ◽

Pharmacological Treatment ◽

Selective Serotonin Reuptake Inhibitors ◽

Evidence Based ◽

Health Related Quality ◽

Pharmacological Treatments ◽

Related Quality ◽

Health Related

This chapter reviews standard pharmacological treatments for OCD and the evidence supporting them. Selective serotonin reuptake inhibitors (SSRIs) remain the pharmacological treatment of choice and are associated with improved health-related quality of life. Improvements are usually sustained over time as long as treatment is continued. Discontinuation is associated with relapse and loss of quality of life, implying that treatment should continue long-term. A substantial minority of patients who fail to respond to SSRIs may benefit from dose elevation, switch to clomipramine, or adjunctive antipsychotic, though long-term trials validating the effectiveness and tolerability of these strategies are relatively lacking.

Download Full-text

Non-Pharmacological Treatment of ADHD Across the Lifespan

European Psychiatry ◽

10.1016/j.eurpsy.2017.01.157 ◽

2017 ◽

Vol 41 (S1) ◽

pp. S33-S33

Author(s):

A. Philipsen

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Risk Factor ◽

Attention Deficit ◽

Pharmacological Treatment ◽

Psychosocial Interventions ◽

Phase Iii ◽

Evidence Based ◽

Hyperactivity Disorder ◽

Psychosocial Consequences ◽

Phase Iii Studies

Attention Deficit Hyperactivity Disorder (ADHD) is a serious risk factor for co-occurring psychiatric disorders and negative psychosocial consequences over the lifespan. Given this background, there is a need for an effective treatment of ADHD patients.In the lecture, evidence-based psychosocial interventions for ADHD will be presented.Disclosure of interestBooks and articles on ADHD.Ad Boards, Phase-III Studies on ADHD in the last five years.

Download Full-text

Clinical status after two-weeks of antidepressant treatment: A prognostic factor in unipolar major depression?

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.1478 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S409-S409

Author(s):

I. Domínguez ◽

L. Nuño ◽

G. Oriolo ◽

R. Quintero ◽

V. Navarro ◽

...

Keyword(s):

Major Depression ◽

Pharmacological Treatment ◽

Depressive Episode ◽

Antidepressant Treatment ◽

Clinical Status ◽

Treatment Protocol ◽

Unipolar Depression ◽

Therapeutic Decisions ◽

Competing Interest ◽

Unipolar Major Depression

Although most unipolar depression clinical guidelines advise against evaluating the efficacy of antidepressant pharmacological treatment until it has been administered in therapeutic doses for a minimum of 4–6 weeks, there is an increasing tendency to make therapeutic decisions after only 2 weeks of treatment. We present a study which aim is to determine whether the clinical course, following 2 weeks of antidepressant treatment, allows therapeutic decisions to be made for patients affected by a moderate/severe depressive episode. The study has an 8-week, prospective, observational design in which all consecutive in- and outpatients with moderate/severe unipolar major depression aged over 17 years received antidepressant treatment based on a standardized treatment protocol. Clinical status was assessed at baseline and at 2-, 4-, and 8-weeks. The final sample consisted of a total of 114 subjects. In our sample, the rate of remitters versus non-remitters was similar between the 2-week improvers and the 2-week non-improvers. It should also be emphasized that it was not possible to explain, based on the epidemiological and clinical characteristics assessed, which 2-week non-improvers would tend towards remission and which would show a partial or full response. Based on these results, for patients affected by a moderate/severe unipolar depressive episode, it would not be appropriate to make new therapeutic decisions following 2 weeks of anti-depressive pharmacological treatment depending on whether the patient has shown clinical improvement or not.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text